Cargando…

No effects of mitomycin-C in primary trabeculectomies in Sweden

AIM: To evaluate the results of a long-term follow-up after two different types of surgical techniques: trabeculectomy with or without mitomycin-C. MATERIALS AND METHODS: This study is a retrospective chart review of patients operated on with a primary trabeculectomy at the Eye Department of the Ska...

Descripción completa

Detalles Bibliográficos
Autor principal: Ayala, Marcelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024500/
https://www.ncbi.nlm.nih.gov/pubmed/29977549
http://dx.doi.org/10.1177/2050312118782262
_version_ 1783336068135780352
author Ayala, Marcelo
author_facet Ayala, Marcelo
author_sort Ayala, Marcelo
collection PubMed
description AIM: To evaluate the results of a long-term follow-up after two different types of surgical techniques: trabeculectomy with or without mitomycin-C. MATERIALS AND METHODS: This study is a retrospective chart review of patients operated on with a primary trabeculectomy at the Eye Department of the Skaraborg Hospital, Skövde, Sweden. Complete success was defined as intraocular pressure ⩽18 mmHg (criterion 1) or intraocular pressure reduction ⩾30% (criterion 2) without eye drops postoperatively. Qualified success was defined using the same criteria (1 and 2), but patients were treated or untreated with eye-drops. RESULTS: A total of 167 patients were included in this retrospective study, 83 patients in the no-mitomycin-C group and 84 patients in the mitomycin-C-treated group. No significant difference was found in intraocular pressure reduction between the mitomycin-C and no-mitomycin-C group (t-test; p = 0.19). Complete success using criterion 1 was 66.2% in no-mitomycin-C and 62.8% in mitomycin-C (p = 0.88); success using criterion 2 was 76.6% in the no-mitomycin-C and 64.2% in the mitomycin-C group (p = 0.21). Qualified success using criterion 1 was 71.4% in the no-mitomycin-C and 74.4% in the mitomycin-C group (p = 0.84); success using criterion 2 was 80.0% in the no-mitomycin-C and 84.4% in the mitomycin-C group. All included patients were born in Sweden. CONCLUSION: Mitomycin-C seems to add no benefits to intraocular pressure reduction after primary trabeculectomies in a Swedish population.
format Online
Article
Text
id pubmed-6024500
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-60245002018-07-05 No effects of mitomycin-C in primary trabeculectomies in Sweden Ayala, Marcelo SAGE Open Med Original Article AIM: To evaluate the results of a long-term follow-up after two different types of surgical techniques: trabeculectomy with or without mitomycin-C. MATERIALS AND METHODS: This study is a retrospective chart review of patients operated on with a primary trabeculectomy at the Eye Department of the Skaraborg Hospital, Skövde, Sweden. Complete success was defined as intraocular pressure ⩽18 mmHg (criterion 1) or intraocular pressure reduction ⩾30% (criterion 2) without eye drops postoperatively. Qualified success was defined using the same criteria (1 and 2), but patients were treated or untreated with eye-drops. RESULTS: A total of 167 patients were included in this retrospective study, 83 patients in the no-mitomycin-C group and 84 patients in the mitomycin-C-treated group. No significant difference was found in intraocular pressure reduction between the mitomycin-C and no-mitomycin-C group (t-test; p = 0.19). Complete success using criterion 1 was 66.2% in no-mitomycin-C and 62.8% in mitomycin-C (p = 0.88); success using criterion 2 was 76.6% in the no-mitomycin-C and 64.2% in the mitomycin-C group (p = 0.21). Qualified success using criterion 1 was 71.4% in the no-mitomycin-C and 74.4% in the mitomycin-C group (p = 0.84); success using criterion 2 was 80.0% in the no-mitomycin-C and 84.4% in the mitomycin-C group. All included patients were born in Sweden. CONCLUSION: Mitomycin-C seems to add no benefits to intraocular pressure reduction after primary trabeculectomies in a Swedish population. SAGE Publications 2018-06-18 /pmc/articles/PMC6024500/ /pubmed/29977549 http://dx.doi.org/10.1177/2050312118782262 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Ayala, Marcelo
No effects of mitomycin-C in primary trabeculectomies in Sweden
title No effects of mitomycin-C in primary trabeculectomies in Sweden
title_full No effects of mitomycin-C in primary trabeculectomies in Sweden
title_fullStr No effects of mitomycin-C in primary trabeculectomies in Sweden
title_full_unstemmed No effects of mitomycin-C in primary trabeculectomies in Sweden
title_short No effects of mitomycin-C in primary trabeculectomies in Sweden
title_sort no effects of mitomycin-c in primary trabeculectomies in sweden
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024500/
https://www.ncbi.nlm.nih.gov/pubmed/29977549
http://dx.doi.org/10.1177/2050312118782262
work_keys_str_mv AT ayalamarcelo noeffectsofmitomycincinprimarytrabeculectomiesinsweden